Skip to content

Development of carbamazepine (CBZ) detection kit (fluorescence immunochromatography)

Development of carbamazepine (CBZ) detection kit (fluorescence immunochromatography)

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400081963
Enrollment
Unknown
Registered
2024-03-18
Start date
2024-03-18
Completion date
Unknown
Last updated
2024-03-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Trigeminal neuralgia, epilepsy

Interventions

Case series:None

Sponsors

Huzhou Central Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients who have been taking carbamazepine continuously for seven days or more

Exclusion criteria

Exclusion criteria: 1) If the sample is stored for more than the expiration date (2-8 ?, stored in dark for more than 4 days); 2) Those who cannot take care of themselves in life; 3) Individuals with no autonomous consciousness or extremely unstable emotions; 4) Other patients who cannot cooperate with sampling and information collection.

Design outcomes

Primary

MeasureTime frame
Blood concentration of Carbamazepine by fluorescence immunochromatography;

Secondary

MeasureTime frame
Blood concentration of Carbamazepine by mass spectrometry;

Countries

China

Contacts

Public ContactMinmin Shen

Huzhou Central Hospital

15715896580@126.com+86 157 1589 6580

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026